VYNDAQEL® OR VYNDAMAX™ Principal Display Panel (tafamidis meglumine or tafamidis)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRINCIPAL DISPLAY PANEL - 20 mg Capsule Blister Card

NDC 0069-1975-12

Vyndaqel®
(tafamidis meglumine) capsules

20 mg per capsule

Pfizer Labs.
LOT/EXP

PEEL & PUSH

PRINCIPAL DISPLAY PANEL - 20 mg Capsule Blister Card Carton

Vyndaqel® 20 mg per capsule*

(tafamidis meglumine) capsules

Attention Pharmacist: Vyndaqel is NOT substitutable on a per mg basis
with other tafamidis products.

NOT FOR INDIVIDUAL RESALE

Pfizer

Contains: A total of 30 capsules per carton.
Each carton contains 3 blister cards. Each
blister card contains 10 capsules.

Rx only

PRINCIPAL DISPLAY PANEL - 20 mg Capsule Blister Card Carton Carton

NDC 0069-1975-40

Vyndaqel®
20 mg per capsule*

(tafamidis meglumine) capsules

Attention Pharmacist: Vyndaqel is NOT substitutable on a per mg basis with other
tafamidis products.

Pfizer

Contains: A total of 120 capsules per carton.
Each carton contains 4 intermediary cartons.
Each intermediary carton contains 3 blister
cards. Each blister card contains 10 capsules.

Rx only

PRINCIPAL DISPLAY PANEL - 20 mg Capsule Blister Card Carton Carton

PRINCIPAL DISPLAY PANEL - 61 mg Capsule Blister Card

NDC 0069-8730-01

Vyndamax™
(tafamidis) capsules

61 mg per capsule

Pfizer Labs.
LOT/EXP

PEEL & PUSH

PRINCIPAL DISPLAY PANEL - 61 mg Capsule Blister Card Carton

NDC 0069-8730-30

Vyndamax™
(tafamidis) capsules

61 mg per capsule

Attention Pharmacist: Vyndamax is NOT substitutable on a per mg basis with
tafamidis meglumine products.

Pfizer

Contains: A total of 30 capsules per carton.
Each carton contains 3 blister cards. Each
blister card contains 10 capsules.

Rx only

PRINCIPAL DISPLAY PANEL - 61 mg Capsule Blister Card Carton

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

VYNDAQEL® OR VYNDAMAX™ Quick Finder

VYNDAQEL® OR VYNDAMAX™ Dose Conversion
Report an adverse event or concern about the quality of a Pfizer product

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly by visiting www.fda.gov/medwatch or by calling (800)-332-1088.
Assistance programs (for eligible patients)

Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Patients and physicians can contact RxPathways at (866) 706-2400 or visit the website for more information on these programs www.pfizerrxpathways.com.
Resources

Show All Hide All